In December 2023, SetPoint Medical, a company based in Valencia, California, reported that patients with moderate to severe rheumatoid arthritis who received brief daily pulses of electrical current to their vagus nerve saw significant drops in disease activity, without adding a single new drug to their regimen. The trial, run across multiple U.S. sites with a randomized, sham-controlled design, is the largest test yet of an idea that started as a strange lab finding two decades ago: that the immune system has an on-off switch, and it runs through a nerve rather than a bloodstream.
This matters because rheumatoid arthritis treatment has been stuck on one axis for twenty five years. You take a biologic drug like adalimumab or etanercept, it blocks a specific inflammatory molecule called TNF-alpha, and for a meaningful fraction of patients it works well. For the rest, it doesn’t work, stops working, or comes with a tradeoff: suppress TNF systemically and you also suppress your ability to fight off infections and certain cancers. SetPoint’s device doesn’t flood the body with a drug. It asks the nervous system to turn down inflammation the way it already knows how.
The Rat Study That Started This Whole Field
The origin point is Kevin Tracey’s lab at what is now the Feinstein Institutes for Medical Research on Long Island. In the late 1990s, Tracey and his colleagues were studying sepsis when they noticed that rats with severed vagus nerves produced far more TNF-alpha than rats with intact ones. Stimulating the vagus nerve, meanwhile, suppressed the inflammatory response throughout the body, not just locally. Tracey named this the cholinergic anti-inflammatory pathway: acetylcholine released by vagal nerve fibers binds to a receptor called alpha-7 nicotinic on macrophages, the immune cells that manufacture TNF, and tells them to stand down.
Stimulate the vagus, dial down the inflammation. Cut the vagus, lose the brake.
That single mechanism, discovered in rodents, is the entire scientific basis for what’s now being tested in humans with rheumatoid arthritis. It took until 2016 for the first real human data to appear, when Frieda Koopman and the late Paul-Peter Tak, working at the Academic Medical Center in Amsterdam in collaboration with SetPoint, implanted a small stimulator on the cervical vagus nerve of a cohort of RA patients who had failed conventional treatment. Published in the Proceedings of the National Academy of Sciences, that pilot study showed that stimulation suppressed TNF production in whole blood cultures and produced clinically meaningful drops in disease activity scores in most of the patients who received it. It was a small study. It was also the first time anyone had shown, in living humans, that flipping a switch on a nerve could quiet an autoimmune disease.
What the Implant Actually Does All Day
The current SetPoint device is a microregulator roughly the size of a large vitamin capsule, implanted surgically around the cervical vagus nerve in the neck through an outpatient procedure. It isn’t running constantly. Patients use a handheld controller to trigger short stimulation sessions, typically lasting well under a minute, once or twice a day. The dose is tiny compared to vagus nerve stimulators used for epilepsy or depression, where the LivaNova (formerly Cyberonics) device runs near-continuous cycles. RA patients are essentially giving their macrophages a brief reminder, a few times daily, to stop overproducing TNF.
That difference in dosing philosophy is the whole design bet. Epilepsy VNS is trying to interrupt an electrical storm as it happens. The RA device is trying to recruit a slower biological pathway, the kind that takes weeks to show its full effect, the same way a biologic drug does. Patients in the Koopman study and in later work didn’t feel a sudden change. Symptom relief built gradually over the treatment period, tracking with measured drops in circulating TNF and in a composite disease severity score called DAS28 that rheumatologists use to grade how many joints are swollen, tender, and how a patient rates their own pain.
What the Newer Numbers Actually Showed
SetPoint’s pivotal trial, run under the name RESET-RA, moved past the small Amsterdam pilot into a properly blinded, sham-controlled design, the kind regulators want to see before anything gets near approval. Patients were randomized to receive either active stimulation or a sham procedure where the implant sat inert, and neither patients nor the clinicians assessing them knew which group was which until the data was unblinded. The company’s topline announcement in late 2023 reported that the trial met its primary endpoint, with a clear separation between the stimulated group and the sham group on standard RA response measures like ACR20, the threshold rheumatologists use to define a meaningful clinical improvement.
The immune system has an off switch, and it runs through a nerve.
That’s a genuinely different kind of result than the 2016 pilot, because sham-controlled data is what turns “interesting mechanism” into “candidate therapy.” It’s also worth being honest about what topline, company-reported results are and aren’t. They aren’t yet a peer-reviewed publication with full statistical detail, adverse event tables, and independent analysis. Trial sponsors have an obvious incentive to frame their own numbers favorably, and the RA field has been burned before by early device and drug results that looked strong in press releases and shrank once the full data came out. The mechanism here is real and well-documented going back to Tracey’s original work. The magnitude of clinical benefit in a real-world patient population, sustained over years rather than months, is still an open question.
Why This Doesn’t Replace Your Rheumatologist Yet
Here’s the honest limitation. Rheumatoid arthritis is a chronic, progressive disease, and the patients who’d be candidates for an implanted device are typically the ones who’ve already failed methotrexate and one or more biologics. That’s a real population, a meaningfully large one, but it’s a fraction of the roughly 1.3 million Americans living with RA, most of whom are adequately controlled on pills or injections they don’t have to have surgically placed in their neck. An implant carries surgical risk, however small, plus the ordinary risks of any vagus nerve stimulator: voice changes, throat discomfort, and in rare cases changes in heart rate, since the vagus nerve also regulates cardiac function.
There’s also a durability question nobody can answer yet. Biologic drugs have fifteen to twenty years of real-world data on how efficacy holds up, how patients cycle through different agents when one stops working, and what happens with long-term infection risk. SetPoint’s device has years, not decades, of human data. Whether stimulated macrophages stay quiet indefinitely, or whether the immune system adapts and the effect fades the way it sometimes does with drugs, is genuinely unknown.
The Real Comparison Is a Weekly Injection, Not a Miracle
The more useful way to think about this device isn’t as a cure but as a different delivery mechanism competing with an entrenched one. Biologic drugs work by flooding the entire body with a molecule that blocks TNF everywhere, all the time, whether or not inflammation is actually happening in a given joint on a given day. The implant tries to work only through the specific circuit that regulates immune activation, in principle sparing the rest of the body’s defenses.
| Approach | Mechanism | Administration | Key tradeoff |
|---|---|---|---|
| SetPoint vagus nerve implant | Activates cholinergic anti-inflammatory pathway, suppresses macrophage TNF production | Surgical implant, patient-triggered daily stimulation | Invasive upfront, unknown long-term durability |
| Adalimumab (Humira) and similar biologics | Systemically binds and blocks circulating TNF-alpha | Injection, typically every one to two weeks | Ongoing infection risk, non-response in a large subset of patients |
| LivaNova VNS (epilepsy indication) | Interrupts abnormal electrical activity via vagal afferents | Implanted, near-continuous cyclic stimulation | Established safety record, different dosing target entirely |
The LivaNova comparison matters for a practical reason: regulators and surgeons already have twenty five years of safety data on implanting devices around the human vagus nerve, from the epilepsy and depression indications approved starting in 1997. SetPoint isn’t asking anyone to trust an unfamiliar piece of hardware. It’s asking them to trust a familiar piece of hardware doing an unfamiliar job.
What Happens if This Actually Gets Approved
If SetPoint’s device eventually clears the FDA for rheumatoid arthritis, the interesting fight won’t be scientific, it’ll be about who gets offered it and when. Insurers are used to paying for biologics because the cost, however high, is at least familiar and reversible: stop the injections, the drug leaves the system in weeks. An implant is a different kind of commitment, and payers will want to know whether it’s cheaper over a five-year horizon than a patient’s current biologic, and whether rheumatologists will offer it as a third-line option after two failed drugs or push it earlier, to patients who’d rather not be on a lifelong injection at all.
The bet underneath all of it is Kevin Tracey’s original finding from a Long Island lab bench: that the body already has a working dial for inflammation, and medicine’s job is just to find it and turn it. SetPoint’s trial results suggest that dial exists in humans, not just rats, and that turning it can look a lot like a drug working, without being one. Whether that holds up over years, in a broader population, at a cost systems are willing to pay, is the trial nobody has run yet.